Indeed, we provided evidence that not only TG2 can be considered a good prognostic marker in melanoma, but also that its expression could affect tumor interplay with the microenvironment via regulating infiltrating immune cells, so that TG2 may be taken into account as a possible predictive immunotherapeutic biomarker in SKCM. The gene discussed is TGM2; the disease is melanoma.